The woolly mammoth, extinct from our planet for thousands of years, has long fascinated scientists. The idea of bringing it back to life was, until recently, nothing but a dream. However, an American biotechnology company named Colossal Biosciences seems on the verge of turning this dream into reality.
Colossal's main goal is ambitious: it aims to resurrect extinct species through a process called de-extinction. Specifically, the company seeks to create a hybrid between the Asian elephant and the woolly mammoth. This creature would have the distinctive physical characteristics of the mammoth, such as its dense fur and its ability to withstand the cold.
The key to this process lies in cell reprogramming. Scientists at Colossal have successfully reprogrammed elephant skin cells to act as embryonic cells. These cells, known as induced pluripotent stem cells, have the ability to differentiate into various cell types, then giving the freedom to create any specific tissue.
This breakthrough represents a giant leap in the field of biotechnology. However, it has elicited both excitement and skepticism within the scientific community. Some researchers emphasize the need for additional validations to ensure the stability and functionality of the obtained pluripotent stem cells. Moreover, the project raises ethical and practical questions. For instance, what will the implications be for ecosystems and existing species if the woolly mammoth is brought back to life? And how can the well-being of these recreated creatures be ensured?
Despite these challenges, Colossal Biosciences remains determined to pursue its goal. With ongoing research to create artificial wombs and explore the necessary genetic modifications, the company hopes to see the first modern mammoth by 2028. This project is not limited to the mere revival of an extinct species. It also offers unique opportunities for research and to raise awareness about conservation issues and modern biotechnology.
Article's author: Cédric DEPOND